In a report released today, Mayank Mamtani from B.Riley Financial reiterated a Buy rating on Agenus (AGEN – Research Report), with a price target of $8.00. The company’s shares opened today at $1.46.
According to TipRanks, Mamtani is an analyst with an average return of -22.8% and a 22.62% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Agenus, Novavax, and Arrowhead Pharmaceuticals.
Agenus has an analyst consensus of Strong Buy, with a price target consensus of $7.66, which is a 424.66% upside from current levels. In a report released on August 8, Robert W. Baird also reiterated a Buy rating on the stock with a $8.00 price target.
See today’s best-performing stocks on TipRanks >>
AGEN market cap is currently $573.2M and has a P/E ratio of -1.80.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes AGEN1884, AGEN2034, INCAGN1876, INCAGN1949, Prophage, AutoSynVax, PhosphoSynVax, and AS-21 Stimulon. The company was founded by Garo H. Armen and Pramod K. Srivastava in March 1994 and is headquartered in Lexington, MA.
Read More on AGEN:
- Biotech Alert: Searches spiking for these stocks today
- Billionaire Steve Cohen Loads Up on These 2 ‘Strong Buy’ Penny Stocks — Here’s Why Wall Street Sees Over 500% Upside Potential
- Agenus reports Q2 EPS (20c), consensus (20c)
- AGEN Earnings this Week: How Will it Perform?
- Jasper Therapeutics appoints Carlos as SVP, Marcantonio as VP
